A prognostic DNA signature for T1T2 node‐negative breast cancer patients

Predicting evolution of small node‐negative breast carcinoma is a real challenge in clinical practice. The aim of this study was to search whether qualitative or quantitative DNA changes may help to predict metastasis of small node‐negative breast carcinoma. Small invasive ductal carcinomas without axillary lymph node involvement (T1T2N0) from 168 patients with either good (111 patients with no event at 5 years after diagnosis) or poor (57 patients with early metastasis) outcome were analyzed with comparative genomic hybridization (CGH) array. A CGH classifier, identifying low‐ and high‐risk groups of metastatic recurrence, was established in a training set of 78 patients, then validated, and compared with clinicopathological parameters in a distinct set of 90 patients. The genomic status of regions located on 2p22.2, 3p23, and 8q21‐24 and the number of segmental alterations were defined in the training set to classify tumors into low‐ or high‐risk groups. In the validation set, in addition to estrogen receptors and grade, this CGH classifier provided significant prognostic information in multivariate analysis (odds ratio, 3.34; 95% confidence interval 1.01–11.02; P = 4.78 × 10−2, Wald test). This study shows that tumor DNA contains important prognostic information that may help to predict metastasis in T1T2N0 tumors of the breast. © 2010 Wiley‐Liss, Inc.

[1]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[2]  Emmanuel Barillot,et al.  Spatial normalization of array-CGH data , 2006, BMC Bioinformatics.

[3]  J. Bergh,et al.  The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[5]  C. Schlotter,et al.  C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer , 2003, Breast Cancer Research.

[6]  Daniel Birnbaum,et al.  Integrated profiling of basal and luminal breast cancers. , 2007, Cancer research.

[7]  Philippe Dessen,et al.  Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array , 2009, Clinical Cancer Research.

[8]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[9]  S. Devries,et al.  Invasive micropapillary carcinoma of the breast is associated with chromosome 8 abnormalities detected by comparative genomic hybridization. , 2002, Human pathology.

[10]  C Caldas,et al.  Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers , 2007, Oncogene.

[11]  S. Hirohashi,et al.  Prognostic significance of accumulation of gene and chromosome alterations and histological grade in node-negative breast carcinoma. , 1998, Japanese journal of clinical oncology.

[12]  Emmanuel Barillot,et al.  Analysis of array CGH data: from signal ratio to gain and loss of DNA regions , 2004, Bioinform..

[13]  Yi Zhang,et al.  Copy number alterations that predict metastatic capability of human breast cancer. , 2009, Cancer research.

[14]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[15]  F. Pépin,et al.  Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.

[16]  Sarah A. Pendergrass,et al.  A Core MYC Gene Expression Signature Is Prominent in Basal-Like Breast Cancer but Only Partially Overlaps the Core Serum Response , 2009, PloS one.

[17]  A. Ashworth,et al.  Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast , 2008, The Journal of pathology.

[18]  H. Moch,et al.  DNA sequence losses on chromosomes 11p and 18q are associated with clinical outcome in lymph node-negative ductal breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  A. Cusmai,et al.  Adjuvant strategies in breast cancer: new prospectives, questions and reflections at the end of 2007 St Gallen International Expert Consensus Conference. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  A. Vincent-Salomon,et al.  Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity , 2007, Breast Cancer Research.

[21]  Ajay N. Jain,et al.  Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. , 2006, Cancer cell.

[22]  Y. Pekarsky,et al.  FHIT: from gene discovery to cancer treatment and prevention. , 2002, The Lancet. Oncology.

[23]  S. Culine,et al.  Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. , 2000, Cancer research.

[24]  Hongjuan Zhao,et al.  TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer , 2007, Breast Cancer Research.

[25]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.

[26]  Alan Mackay,et al.  FGFR1 Emerges as a Potential Therapeutic Target for Lobular Breast Carcinomas , 2006, Clinical Cancer Research.

[27]  A. Ashworth,et al.  Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast Cancers , 2009, Clinical Cancer Research.

[28]  N. Carter,et al.  A comprehensive study of chromosome 16q in invasive ductal and lobular breast carcinoma using array CGH , 2006, Oncogene.

[29]  Carlos Caldas,et al.  A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the Proliferation, Immune response and RNA splicing modules in breast cancer , 2008, Breast Cancer Research.

[30]  O. Lingjaerde,et al.  ESR1 gene amplification in breast cancer: a common phenomenon? , 2008, Nature Genetics.

[31]  R. Zeillinger,et al.  Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. , 1997, Cancer research.

[32]  Olivier Delattre,et al.  Two types of chromosome 1p losses with opposite significance in gliomas , 2005, Annals of neurology.

[33]  M. Kaminski,et al.  Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. , 2007, Blood.

[34]  Céline Rouveirol,et al.  VAMP: Visualization and analysis of array-CGH, transcriptome and other molecular profiles , 2006, Bioinform..

[35]  B. Dutrillaux,et al.  carcinomas: cytogenetic and clinicopathological , 2022 .

[36]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[37]  Jorma Isola,et al.  Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. , 2003, Cancer research.

[38]  Z. Szallasi,et al.  A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers , 2006, Nature Genetics.

[39]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[40]  Gudrun Schleiermacher,et al.  Overall genomic pattern is a predictor of outcome in neuroblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Peter Schraml,et al.  Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer , 2004, Cancer Research.

[42]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[43]  S. Tavaré,et al.  High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer , 2007, Genome Biology.

[44]  Robert Tibshirani,et al.  Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene‐expression subtypes of breast cancer , 2006, Genes, chromosomes & cancer.